Price T Rowe Associates Inc. MD cut its stake in Merus (NASDAQ:MRUS - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,116,820 shares of the biotechnology company's stock after selling 165,160 shares during the period. Price T Rowe Associates Inc. MD owned about 1.63% of Merus worth $46,963,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wells Fargo & Company MN lifted its holdings in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 300 shares during the last quarter. Geode Capital Management LLC raised its stake in Merus by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 52,636 shares of the biotechnology company's stock valued at $2,213,000 after acquiring an additional 540 shares during the last quarter. HighTower Advisors LLC lifted its position in Merus by 10.9% during the 4th quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company's stock worth $337,000 after acquiring an additional 789 shares during the period. Harbor Capital Advisors Inc. grew its stake in shares of Merus by 2.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 43,208 shares of the biotechnology company's stock valued at $1,817,000 after purchasing an additional 921 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in shares of Merus by 9.6% in the fourth quarter. Arizona State Retirement System now owns 13,833 shares of the biotechnology company's stock valued at $582,000 after acquiring an additional 1,209 shares in the last quarter. 96.14% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the stock. Piper Sandler began coverage on shares of Merus in a research note on Thursday, February 13th. They set an "overweight" rating and a $84.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $85.00 price target on shares of Merus in a report on Monday, March 3rd. Wells Fargo & Company assumed coverage on shares of Merus in a report on Friday, February 7th. They issued an "overweight" rating and a $91.00 target price for the company. Needham & Company LLC restated a "buy" rating and issued a $83.00 price target on shares of Merus in a research note on Wednesday, April 9th. Finally, Bank of America decreased their price target on shares of Merus from $73.00 to $70.00 and set a "buy" rating for the company in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Merus presently has a consensus rating of "Buy" and an average price target of $85.31.
Check Out Our Latest Research Report on MRUS
Merus Stock Down 2.8 %
Shares of Merus stock traded down $1.26 during trading on Friday, reaching $44.19. 705,630 shares of the stock were exchanged, compared to its average volume of 710,401. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of -11.19 and a beta of 0.94. Merus has a 1 year low of $33.19 and a 1 year high of $61.61. The stock's fifty day moving average is $43.96 and its 200 day moving average is $44.53.
Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.48. The company had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. Equities analysts forecast that Merus will post -3.85 earnings per share for the current year.
Merus Profile
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Featured Articles
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
